Is Globus Medical (GMED) Pricing Look Attractive After Recent Sideways Share Performance
This article analyzes Globus Medical's (GMED) stock valuation using two methods: Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio. The DCF analysis suggests GMED is undervalued by 25.8%, with an intrinsic value of $118.77 per share compared to its current price of $88.09. However, the P/E ratio of 27.82x, which is above its 'Fair Ratio' of 23.99x, indicates the stock might be overvalued based on this metric.
Globus Medical (GMED) Valuation Check After Mixed Short Term Returns And 16.6% Undervaluation View
Globus Medical (GMED) is currently trading around $88.72, with recent share price returns being mixed, suggesting a cooling of short-term momentum despite stronger long-term performance. Valuation models, particularly one widely followed narrative, suggest the stock is 16.6% undervalued, with a fair value of $106.40, driven by innovation in robotics and minimally invasive procedures. However, the article notes potential execution risks from prolonged sales cycles or integration issues that could impact growth and margins.
How Globus Medical’s Robotics and Digitization Push Will Impact Globus Medical (GMED) Investors
Globus Medical (GMED) is attracting attention due to strong fundamentals, a debt-free balance sheet, and rapid expansion in musculoskeletal technologies, including its ExcelsiusGPS robotic platform. While the company's innovation in robotics and digitization presents growth opportunities, it also faces challenges like longer sales cycles and integration post-acquisitions. Investors are weighing these factors, with various fair value estimates suggesting mixed outlooks on the stock's future performance.
Is Globus Medical (GMED) Pricing Fair After The Recent Healthcare Sector Reassessment?
This article analyzes Globus Medical's (GMED) pricing after a healthcare sector reassessment, using discounted cash flow (DCF) and price-to-earnings (P/E) ratio models. The DCF model suggests GMED is 24.3% undervalued, while the P/E ratio indicates it is overvalued compared to its proprietary "Fair Ratio." The article encourages investors to use "Narratives" on Simply Wall St to personalize their valuation based on individual assumptions.
Assessing Globus Medical (GMED) Valuation After Investor Letter Highlights Reaccelerating Spine Growth And Integration Progress
An investor letter from Meridian Growth Fund highlighted Globus Medical's reaccelerating spine business growth and successful integration of prior acquisitions, leading to a recent 50.16% share price increase over 90 days. Despite trading at a premium to its 1-year performance, the stock remains undervalued by 14.8% according to some narratives, with a fair value target of $106.40, driven by innovation in robotics and digital healthcare. However, challenges like slower international progress and ongoing integration work could temper this optimistic outlook.
Is Globus Medical (GMED) Pricing Reflect Its DCF Upside And Mixed P/E Signals?
This article analyzes Globus Medical's (GMED) valuation by using two approaches: Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio. The DCF model suggests the stock is 19.3% undervalued at $114.59 per share compared to its current price of US$92.52. However, its P/E ratio of 29.22x is considered overvalued when compared to Simply Wall St’s Fair Ratio of 22.15x, indicating mixed signals for investors.
Globus Medical (GMED) Valuation Check After Updated Guidance And NuVasive Synergy Outlook
Globus Medical (GMED) has provided updated guidance for 2025 and 2026, driven by its integration with NuVasive. The article evaluates GMED's valuation, noting its P/E ratio of 29.4x is below the peer average but above its estimated fair P/E, while a DCF model suggests an 18.9% discount to fair value. The analysis concludes that the stock is "ABOUT RIGHT" in terms of its P/E compared to peers, but highlights potential risks if NuVasive integration disappoints.
Globus Medical’s Higher 2025–2026 Revenue Guidance Might Change The Case For Investing In Globus Medical (GMED)
Globus Medical Inc. recently provided updated guidance, projecting stronger revenue for Q4 2025 (approximately US$823.2 million) and full-year 2025 (about US$2.94 billion), alongside a new 2026 revenue range of US$3.18 billion to US$3.22 billion. This improved outlook, driven by confidence in its musculoskeletal and enabling technology portfolio and recent acquisitions, could enhance Globus Medical's investment appeal. However, investors should still consider integration risks associated with acquisitions like NuVasive and Nevro, and potential variability in robotic system sales, despite management's ongoing share repurchase activity.
A Look At Globus Medical (GMED) Valuation As Strong 2025 And 2026 Guidance Lifts Investor Confidence
Globus Medical (GMED) has seen renewed investor confidence following strong guidance for 2025 and 2026, projecting sales of US$823.2 million for Q4 2025 and total revenue of US$2.936 billion for 2025, and US$3.18 billion to US$3.22 billion for 2026. Despite a 'narrative fair value' suggesting the stock is slightly undervalued, an analysis of P/E ratios indicates it may be expensive compared to its estimated fair ratio, prompting mixed signals on whether its future growth is already priced in. Investors are encouraged to conduct their own analysis, considering risks like integration challenges and slower market growth.
Globus Medical (GMED) director Norwalk sells $202k in shares By Investing.com
Globus Medical (GMED) director Leslie V. Norwalk sold 2,000 shares of Class A Common Stock for $202,200 on January 8, 2026, under a Rule 10b5-1 trading plan. This sale occurred near the stock's 52-week high after a significant price increase. Despite this director sale, InvestingPro data indicates aggressive share buybacks by management, a perfect Piotroski Score, strong financial health, and potential undervaluation, aligning with recent strong fourth-quarter revenue results that surpassed estimates and led to increased price targets from several analysts.
Globus Medical (GMED) director Norwalk sells $202k in shares By Investing.com
Globus Medical director Leslie V. Norwalk sold 2,000 shares of Class A Common Stock for $202,200. This transaction occurred near the stock's 52-week high, following a significant price increase. Despite the director's sale, the company shows strong financial health with aggressive share buybacks, a Piotroski Score of 9, and appears undervalued according to InvestingPro.
Globus Medical (GMED) director Norwalk sells $202k in shares
Globus Medical Inc (NYSE:GMED) director Leslie V. Norwalk sold 2,000 shares of Class A Common Stock for $202,200 on January 8, 2026, executed under a Rule 10b5-1 trading plan. This sale occurred near the stock's 52-week high after a significant price increase. Despite this director's sale, InvestingPro data indicates aggressive share buybacks by management, a perfect Piotroski Score of 9, and the company appears undervalued with strong financials.
Why Globus Medical (GMED) Is Up 8.2% After Raising 2026 Revenue Guidance And Integration Outlook
Globus Medical (GMED) saw its stock rise by 8.2% after announcing preliminary Q4 and full-year 2025 sales and raising its 2026 revenue guidance to between US$3.18 billion and US$3.22 billion. This optimistic outlook is attributed to strong performance in U.S. Spine and Enabling Technologies, as well as the successful integration of the NuVasive and Nevro acquisitions. The company's investment narrative focuses on long-term demand for musculoskeletal solutions and leveraging technology and acquisitions for sustainable growth, though execution and adoption risks remain.
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
Globus Medical Inc. announced preliminary unaudited sales results for Q4 and full year 2025, reporting anticipated fourth-quarter sales of approximately $823.2 million, a 25.2% increase from 2024, and full-year sales of about $2.936 billion, up 16.5% from the prior year. The company expects 2026 revenue guidance between $3.18 billion and $3.22 billion and diluted non-GAAP earnings per share between $4.30 to $4.40, indicating strong growth momentum driven by US Spine and Enabling Technologies, along with successful integration of recent acquisitions.
Understanding Momentum Shifts in (GMED)
This article analyzes momentum shifts for Globus Medical Inc. Class A (GMED) using AI models. It identifies a neutral sentiment across all horizons, suggesting a wait-and-see approach with elevated downside risk due to a lack of long-term support signals. The analysis provides specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/exit points and stop losses, along with a multi-timeframe signal analysis.
Globus Medical, Inc. Class A Common Stock (NYSE:GMED) Stock Quote
This article provides a stock quote and recent news headlines for Globus Medical, Inc. (NYSE:GMED). It details key financial figures such as volume, open, bid/ask, and ranges, along with performance metrics. The news section highlights analyst upgrades and discussions on the company's financial performance and strategic position in the medical device sector.
Globus Medical (GMED): Assessing Valuation After a 60% Three-Month Share Price Surge
Globus Medical (GMED) has seen its shares surge by approximately 60% over the last three months, outperforming many peers and bringing its valuation into focus. Despite this rally, the stock is still trading below analyst targets and intrinsic value estimates, with a fair value pegged around $95.70, suggesting it remains undervalued. This narrative is primarily driven by expected benefits from the NuVasive and Nevro acquisitions, promising increased cross-selling, cost efficiencies, and margin expansion.
How Investors May Respond To Globus Medical (GMED) Analyst Optimism Around Clinical Trial Momentum
Recent positive analyst views concerning Globus Medical's musculoskeletal and enabling-technology portfolio, coupled with encouraging clinical trial results, are drawing renewed investor attention. This optimism, highlighted by RBC Capital's increased target price, signals a potential reshaping of the company's long-term growth narrative. Investors should, however, remain mindful of ongoing integration risks associated with NuVasive and Nevro despite the promising outlook.
Precision Trading with Globus Medical Inc. Class A (GMED) Risk Zones
This article details precision trading strategies for Globus Medical Inc. Class A (GMED) based on AI-generated signals. It outlines specific entry/exit zones, targets, and stop losses for position trading, momentum breakout, and risk hedging strategies. The analysis indicates a near-term neutral sentiment but suggests prevailing weakness in the mid and long term.
Globus Medical (GMED): Assessing Valuation After a 3-Month 50% Share Price Surge
Globus Medical (GMED) has seen a significant 50% share price surge over the last three months, prompting a re-evaluation of its valuation. Despite this rally, analysts suggest the stock might still be undervalued, with a fair value near $95.70 against a closing price of $85.06. The article explores whether this surge is an early re-rating or if future growth is already priced in, while acknowledging potential risks from integration and slowing spine procedure growth.
Globus Medical (GMED) CFO Kline sells $1.66 million in stock
Kyle Kline, CFO of Globus Medical Inc (GMED), sold 18,542 shares of Class A Common Stock for $1,668,780 and simultaneously exercised options to acquire the same number of shares. This transaction occurred amidst positive analyst sentiment, with Piper Sandler, BofA Securities, and Truist Securities raising their price targets and ratings on GMED following stronger-than-expected third-quarter earnings. Needham, however, maintained a Hold rating despite the earnings beat.
How Investors Are Reacting To Globus Medical (GMED) Earnings Beat, Raised Outlook and CFO Share Sale
Globus Medical (GMED) reported strong third-quarter earnings and revenue, exceeding analyst expectations and leading to a raised full-year guidance. Despite the CFO Kyle Kline selling 18,542 Class A shares, analysts view the improved profitability and growth momentum as the key indicators. The company's investment narrative focuses on long-term demand for spine and orthopedic solutions, with ongoing share repurchases supporting the equity story, while integration risks with NuVasive and Nevro remain.
Globus Medical (GMED): Reassessing Valuation After Recent Share Price Momentum
Globus Medical (GMED) has experienced a significant share price increase of approximately 47% in the past month, leading to a reassessment of its valuation. Despite this surge, the stock is considered "2.4% Undervalued" with a narrative fair value of $91.20, driven by anticipated benefits from recent acquisitions. However, current P/E ratios suggest limited cushion if growth expectations are not met, prompting investors to consider various valuation lenses.
How Should Investors View Globus Medical After Its 44% Surge and Mergers Buzz?
Globus Medical (NYSE: GMED) has seen its shares surge by 44% in the last month, driven by mergers buzz in the medical device sector. Despite this, Simply Wall St's analysis suggests the stock is significantly overvalued based on a Discounted Cash Flow (DCF) model, pinpointing an intrinsic value of $17.25 per share against current trading levels. While its price-to-earnings (PE) ratio is aligned with the industry average, it appears overstretched when compared to its calculated "Fair Ratio," indicating a premium valuation not supported by its underlying risk and growth profile.
Globus Medical SVP Huller sells shares for $675,000
Kelly Huller, SVP at Globus Medical Inc (NASDAQ:GMED), sold 7,500 shares for $675,000 on November 25, 2025, after exercising options for the same number of shares. This transaction occurred while the company's stock trades near its 52-week high, showing strong performance and a perfect Piotroski Score of 9. Recent positive financial results led several analysts to raise their price targets and ratings on GMED.
Globus Medical (GMED): Assessing Valuation Following Strong Q3 Results and Upgraded Guidance
Globus Medical (GMED) saw a 4% jump in its share price after announcing strong Q3 results and raising its full-year outlook. The company's valuation is considered "About Right" at $88.80, with analysts factoring in successful integration of recent acquisitions and expected profitability leaps. However, its P/E ratio of 27.8x is slightly above the industry average, sparking debate about potential valuation risk despite market confidence in long-term outperformance.
Is Globus Medical’s (GMED) Raised 2025 Guidance Changing the Investment Case for Investors?
Globus Medical (GMED) recently increased its full-year 2025 guidance for revenue and adjusted earnings following strong third-quarter results. This positive outlook, influenced by operational improvements and potential interest rate cuts, suggests a refined investment case for the company. However, investors should remain mindful of ongoing integration challenges from recent acquisitions and international market pressures.
Davidar, Globus Medical director, sells $2.15m in Gmed stock
Davidar David D., a director at Globus Medical Inc (NASDAQ:GMED), sold 25,000 shares of Class A Common Stock for $2.15 million on November 12, 2025, after exercising options for the same number of shares. This transaction follows strong third-quarter 2025 financial results for Globus Medical, which exceeded revenue and earnings expectations, leading several analysts to upgrade their ratings and price targets for the stock.
Davidar, Globus Medical director, sells $2.15m in Gmed stock
Globus Medical director Davidar David D. sold 25,000 shares of Class A Common Stock for $2.15 million and exercised options to acquire an additional 25,000 shares for $638,000. Following these transactions, Davidar directly holds 516,275 shares. The sale occurred amidst strong third-quarter 2025 financial results for Globus Medical, which exceeded revenue and earnings expectations, leading several analysts to upgrade the stock or raise price targets.
Globus Medical Reports Third Quarter 2025 Results
Globus Medical (NYSE: GMED) announced strong financial results for Q3 2025, with worldwide net sales increasing 22.9% to $769.0 million, and non-GAAP diluted EPS rising 42.6% to $1.18. The company's Nevro acquisition exceeded expectations, contributing significantly to revenue growth and profitability. Globus Medical has also raised its full-year 2025 guidance for both revenue and non-GAAP EPS, anticipating the Nevro acquisition to be accretive to earnings.
Globus Medical (GMED): Evaluating Valuation After Launch of Innovative ANTHEM Elbow Fracture System
Globus Medical has launched its new ANTHEM Elbow Fracture System, designed to address complex elbow fractures, which has led to a 12.4% rise in its share price over 90 days. Despite this, the 1-year total shareholder return is down 18.9%. Analysts believe GMED is undervalued at $80.30, trading at 22.6x P/E, below its industry average, potentially signaling an investment opportunity.
Globus Medical Schedules Third Quarter Earnings Release and Conference Call - Investing News Network
Globus Medical Inc. (NYSE:GMED) will release its third-quarter financial results for 2025 on Thursday, November 6, 2025, after market close. The company will also host a teleconference at 4:30 p.m. Eastern Time to discuss its performance with the investment community. Details for accessing the webcast and telephone participation are provided.
Globus Medical, Inc. to Report Third Quarter Financial Results on November 6, 2025 - Quiver Quantitative
Globus Medical, Inc. will release its third-quarter financial results for 2025 on November 6, 2025, after market close, followed by an investor teleconference. The company will discuss its financial performance and operations, emphasizing its dedication to musculoskeletal technology and addressing unmet clinical needs. The article also details potential positives and negatives, along with recent congressional, insider, hedge fund, and analyst activities related to GMED stock.
Globus Medical Schedules Third Quarter Earnings Release and Conference Call - GlobeNewswire
Globus Medical, Inc. (NYSE: GMED) announced it will release its financial results for the third quarter ended September 30, 2025, after market close on Thursday, November 6, 2025. The company will also host a teleconference at 4:30 p.m. ET to discuss its performance with the investment community. Details for accessing the webcast and telephone participation are provided.
Globus Medical Schedules Third Quarter Earnings Release and Conference Call - Stock Titan
Globus Medical (NYSE: GMED) announced it will release its third-quarter 2025 financial results after market close on Thursday, November 6, 2025. Following the release, the company will host a teleconference and live webcast for the investment community at 4:30 p.m. Eastern Time to discuss its performance. The press release and webcast details will be available on the company's Investors website.
Judge Dings Life Spine Filing in $9.5 Million Globus Patent Case - Bloomberg Law News
A Delaware judge refused to reconsider how a $9.5 million patent infringement verdict for Globus Medical Inc. against Life Spine Inc. counted infringing sales. The judge stated that Life Spine failed to cite where the expert agreement on 62,942 infringing units appeared in the trial record for review.
Judge Dings Life Spine Filing in $9.5 Million Globus Patent Case - Bloomberg Law News
A Delaware judge upheld a $9.5 million patent infringement verdict for Globus Medical Inc. against Life Spine Inc., refusing to reconsider the count of infringing sales. The judge cited Life Spine's failure to provide trial record evidence supporting its claim that experts agreed on the number of infringing units.
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma - Orthopedics This Week
Globus Medical, Inc. (NYSE: GMED) has launched the ANTHEM™ Elbow Fracture System, a comprehensive plating portfolio designed for complex elbow trauma. The system features anatomically contoured plates, 14 plate families, and polyaxial locking technology to simplify surgical workflows and offer versatility for various fracture patterns. This new system reinforces Globus Medical's commitment to advancing trauma care and expanding its Trauma Portfolio.
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma - Ortho Spine News
Globus Medical has launched the ANTHEM™ Elbow Fracture System, a comprehensive plating portfolio designed for various elbow fractures with a simplified workflow. The system features anatomically contoured plates, 14 plate families, and polyaxial locking technology, empowering surgeons to treat complex fracture patterns. This launch further expands Globus Medical's Trauma Portfolio, demonstrating their commitment to innovation in musculoskeletal care.
Globus Medical Launches ANTHEM Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma - Investing News Network
Globus Medical, Inc. has introduced the ANTHEM™ Elbow Fracture System, a new plating portfolio designed for a wide range of elbow fractures. This system offers anatomically contoured plates, polyaxial locking technology, and various screw options to provide surgeons with flexibility and simplify complex surgical procedures. The launch reinforces Globus Medical's commitment to advancing trauma care through innovative musculoskeletal solutions.
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
Globus Medical, Inc. (NYSE: GMED) has launched the ANTHEM™ Elbow Fracture System, a comprehensive plating portfolio for complex elbow trauma. The system features anatomically contoured plates, 14 plate families, 2.7mm and 3.5mm screw options, and polyaxial locking technology to simplify surgical workflows and enhance flexibility. This new system aims to provide surgeons with advanced tools for treating a wide array of elbow fractures, reinforcing Globus Medical's commitment to innovation in trauma care.
Globus Medical launches new elbow fracture system for complex injuries By Investing.com - Investing.com Canada
The article announces that Globus Medical has launched a new elbow fracture system designed for complex injuries. This development reflects an expansion of their product offerings in the medical device sector.
Globus Medical Launches ANTHEM™ Elbow Fracture System to Enhance Surgical Treatment of Elbow Injuries - Quiver Quantitative
Globus Medical, Inc. has introduced the ANTHEM™ Elbow Fracture System, a comprehensive plating portfolio designed to address a wide range of elbow fractures with a simplified surgical workflow. This system features anatomically contoured plates and polyaxial locking technology, empowering surgeons to achieve strong fixation and precise screw placement. The launch reinforces Globus Medical's commitment to innovation in musculoskeletal solutions and advancing trauma care.
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
Globus Medical has launched the ANTHEM™ Elbow Fracture System, a comprehensive plating portfolio designed for complex elbow trauma. This system features anatomically contoured plates, polyaxial locking technology, and various screw options to simplify surgical workflows and provide versatility for surgeons. The launch signifies Globus Medical's ongoing commitment to advancing trauma care with innovative musculoskeletal solutions.
What Globus Medical (GMED)'s CEO Transition Amid Trade Tensions Means For Shareholders
Globus Medical (GMED) recently experienced a CEO transition, with Daniel Scavilla resigning and Keith Pfeil named as his successor, amidst increasing US-China trade tensions. This leadership change introduces investor uncertainty, but continued integration of recent acquisitions and strong Q2 earnings provide some reassurance. The article projects Globus Medical to reach $3.4 billion in revenue and $538.8 million in earnings by 2028, with a fair value of $80.30 representing a 40% upside.
Globus Medical (GMED): Evaluating Valuation After New Products, Growth, and ROIC Slowdown
Globus Medical (GMED) is experiencing revenue and earnings growth with new product launches and international expansion, but its return on invested capital has fallen, leading to share price stagnation. Despite a bullish narrative fair value of $80.30 due to projected growth and innovation, a Discounted Cash Flow (DCF) model suggests overvaluation. Investors are urged to consider both perspectives and conduct their own research.
Globus Medical Secures Jury Verdict in Patent Infringement Case Against Life Spine, Inc.
Globus Medical won a patent infringement case against Life Spine, Inc. regarding expandable spinal fusion implants, with a Delaware jury awarding damages for lost profits and reasonable royalties. CEO Keith Pfeil highlighted the verdict as an affirmation of Globus’s intellectual property and innovation. The company also has ongoing litigation against Alphatec, Inc. concerning similar technology and reiterated its commitment to protecting its patents and investing in patient-focused innovations.
Globus Medical Reports Second Quarter 2025 Results
Globus Medical reported strong financial results for the second quarter of 2025, with worldwide net sales increasing by 18.4% to $745.3 million and GAAP diluted EPS reaching $1.49. The company's US Spine business showed significant growth, and non-GAAP diluted EPS rose to $0.86. Globus Medical reaffirmed its full-year 2025 guidance for revenue and non-GAAP diluted EPS, citing continued momentum, successful integration efforts from M&A, and strategic focus on new product launches and organic growth.
Globus promotes Keith Pfeil to CEO as former exec leaves for Dentsply
Globus Medical has promoted Keith Pfeil to CEO following Daniel Scavilla's resignation to become CEO of Dentsply Sirona. Pfeil, who previously served as COO and CFO, has been with Globus since 2019, and his promotion is seen as a smooth internal succession despite initial market uncertainty. RBC Capital Markets analysts expressed high confidence in the leadership transition given Pfeil's experience and the company's track record of internal promotions.
Globus Medical Appoints Keith Pfeil as CEO
Globus Medical, Inc. announced the appointment of Keith Pfeil as President and Chief Executive Officer, effective July 18, 2025. Daniel Scavilla resigned from the position. Additionally, Kyle Kline was appointed Senior Vice President and Chief Financial Officer. The company also released preliminary second-quarter 2025 sales results and reaffirmed its full-year 2025 revenue and earnings per share guidance.
